Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia

Overview of attention for article published in Cancer Discovery, November 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Dimensions has found 7 publications that cite this research output.

Article in Computational and Structural Biotechnology Journal (July 2024)

Article in Cells (June 2024)

Article in Structure (April 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.